We are international
Donate
• videos TEXT SIZE   
webcasts from medical meetings    back

ASH 2005 Webcast: New Agents and New Opportunities for Multiple Myeloma Today and Tomorrow

A Corporate Friday Symposium preceding the 47th Annual American Society of Hematology Meeting

This CME-certified activity addressed current issues in clinical practice in the context of new agents and new discoveries in the treatment of multiple myeloma in an interactive panel discussion with prominent faculty.

ASH 2005 New Agents And New Opportunities

What is role of high-dose melphalan in the era of new effective agents?
High-Dose Melphalan in the Era of New Effective Agents
Bart Barlogie, MD
University of Arkansas for Medical Sciences
Myeloma Institute for Research and Therapy
Little Rock, Arkansas

The Potential Role of Novel Combinations in Frontline Therapy
Brian G.M. Durie, MD
Cedars Sinai Comprehensive Cancer Center
Los Angeles, California

Does the percentage of complete response with new drugs determine ultimate survival?
The Importance of Achieving Complete Remission (CR)
James D. Cavenagh, MD, MRCP
St. Bartholomew's Hospital
London, England

Does the Percentage of Complete Response with New Drugs Determine Ultimate Survival?
Jean-Luc Harousseau, MD
University Hospital Nantes
Nantes, France

Does maintenance improve time to progression and ultimate survival?
The Safety Issue Surrounding Maintenance Therapy
Antonio Palumbo, MD
Molinette Hospital
Turin, Italy

Does Maintenance Therapy Improve Time to Progression and Ultimate Survival?
James D. Cavenagh, MD MRCP
St. Bartholomew's Hospital
London, England

Is double transplant better than single transplant?
Is Double Transplant Better Than Single Transplant?
Jean-Luc Harousseau, MD
University Hospital Nantes
Nantes, France

Tandem vs Single Transplant: Which is Better for Whom?
Bart Barlogie, MD
University of Arkansas for Medical Sciences
Myeloma Institute for Research and Therapy
Little Rock, Arkansas

Should known effective therapies or new agents be used in patients with relapsed disease?
Role of New Drug Trials at Relapse
Brian G.M. Durie, MD
Cedars Sinai Comprehensive Cancer Center
Los Angeles, California

ASH 2005 Webcast
The IMF is pleased to provide you with a broad sampling of myeloma presentations and posters from the 2005 annual meeting of the American Society of Hematology in San Diego, California. We hope you will find this material informative and useful.